FMO2

FMO2 is an NADPH-dependent, FAD-containing flavoenzyme that classically catalyzes N- and S-oxygenation of drugs and xenobiotics, with characteristic high substrate affinity and prochiral stereoselectivity distinct from other FMO isoforms (PMID:8203899, PMID:1417778). In most humans this canonical activity is lost because the major allele carries a C472X nonsense mutation that truncates 64 C-terminal residues and abolishes catalysis, while only a minority allele (Gln472) found at appreciable frequency in individuals of African ancestry produces full-length, catalytically active enzyme (PMID:9804831, PMID:11042094); reconstitution of full-length versus 3'-truncated orthologs confirms that the C-terminus is required for oxygenation activity despite correct membrane targeting (PMID:11302936). Beyond xenobiotic metabolism, FMO2 has emerged as a multifunctional protein with enzyme-activity-independent scaffolding roles: it binds SREBP1 (residues 217–296) to competitively block SCAP engagement, preventing ER-to-Golgi SREBP1 translocation and proteolytic activation and thereby suppressing de novo lipogenesis (PMID:37874228). In cardiomyocytes FMO2 localizes to mitochondria-associated ER membranes, where it joins the IP3R2-Grp75-VDAC1 complex to sustain ER-mitochondria Ca²⁺ transfer and bioenergetics, and its loss exacerbates while its overexpression prevents pathological cardiac hypertrophy (PMID:40489543). Additional protective cardiac functions include stabilization of chromatin-associated XLF to promote DNA repair against doxorubicin toxicity (PMID:40752568), and its cardiac expression is controlled by an AMPK-KLF4 transcriptional axis (PMID:39491669) and by post-transcriptional suppression through the RNA-binding proteins CELF1 and CELF4 acting on its 3'UTR (PMID:40610856, PMID:40021568).

1. 1992 High

   Establishing FMO2 as a discrete flavoenzyme gene with defined cofactor-binding architecture provided the molecular foundation for studying its catalytic chemistry.

   Evidence cDNA cloning, sequence analysis, Southern blot and chromosomal mapping of human FMO2

   PMID:1417778

   Open questions at the time

   • No enzymatic activity demonstrated in this study
   • Tissue distribution and substrate range not yet defined
2. 1994 High

   Reconstitution of the active enzyme defined FMO2's distinctive catalytic signature, distinguishing it kinetically and stereochemically from sibling FMO isoforms.

   Evidence Rabbit FMO2 expressed in E. coli, sulfoxidation kinetics and stereochemical product analysis

   PMID:8203899

   Open questions at the time

   • Ortholog rather than human enzyme
   • Physiological substrates in vivo not established
3. 1998 High

   Discovery that the predominant human allele is a C472X truncation explained why most humans lack functional pulmonary FMO2, reframing the gene as a polymorphic pseudo-enzyme in most populations.

   Evidence cDNA isolation, sequence analysis, heterologous expression with functional assay

   PMID:9804831

   Open questions at the time

   • Functional consequence of activity loss for human physiology unaddressed
   • Frequency of active allele across populations not quantified here
4. 2001 High

   Side-by-side expression of full-length versus truncated orthologs showed the C-terminus is required for catalysis but not membrane targeting, localizing the functional defect of the truncated allele.

   Evidence Baculovirus expression of full-length and truncated monkey FMO2, N-/S-oxygenation assays, membrane fractionation

   PMID:11302936

   Open questions at the time

   • Monkey ortholog
   • Structural basis for C-terminal requirement not resolved
5. 2009 Medium

   Kinetic dissection of natural FMO2.1 variants mapped residues critical for NADPH binding and thermal stability, linking specific positions to catalytic competence.

   Evidence Heterologous expression of S195L and N413K variants, NADPH Km, thermal stability assays, structural modeling

   PMID:19420133

   Open questions at the time

   • No crystal structure
   • In vivo consequences of variants not tested
6. 2023 High

   Identification of FMO2 binding SREBP1 to block SCAP-dependent activation revealed an enzyme-independent role in restraining lipogenesis, redefining FMO2 as a scaffold/regulator rather than only a metabolizing enzyme.

   Evidence Reciprocal Co-IP/pulldown defining binding domain, hepatocyte and global KO/OE mouse models, RNA-seq, lipogenesis assays

   PMID:37874228

   Open questions at the time

   • Whether catalytic-dead human variants retain this function untested
   • Structural basis of SCAP competition not solved
7. 2024 Medium

   Defining the AMPK-KLF4 axis as a driver of cardiac FMO2 expression connected exercise/energy-sensing signaling to FMO2-dependent cardioprotection.

   Evidence AAV9 FMO2 knockdown in vivo, AMPK activation, KLF4 transcription factor analysis

   PMID:39491669

   Open questions at the time

   • Direct KLF4 binding to FMO2 promoter not detailed
   • Downstream cardioprotective effector of FMO2 not defined in this study
8. 2025 High

   MAM localization within the IP3R2-Grp75-VDAC1 complex established FMO2 as a structural organizer of ER-mitochondria Ca2+ transfer controlling cardiac bioenergetics and hypertrophy.

   Evidence MAM-targeted mass spectrometry, Co-IP, cardiac KO/OE (AAV9), Ca2+ imaging, peptide rescue

   PMID:40489543

   Open questions at the time

   • Direct binding interface within the complex not mapped
   • Whether activity contributes is not separated from scaffolding
9. 2025 Medium

   Demonstration that FMO2 stabilizes chromatin-associated XLF to promote DNA repair added a genome-protective mechanism underlying its defense against cardiotoxic stress.

   Evidence Genetic KO and cardiomyocyte OE mouse models, chromatin analysis, adenoviral KD/OE in NRVMs, xenograft model

   PMID:40752568

   Open questions at the time

   • Mechanism of XLF stabilization (direct binding vs indirect) not resolved
   • Generalizability beyond cardiomyocytes unknown
10. 2025 Medium

    Identification of CELF1 and CELF4 as 3'UTR-binding suppressors of FMO2 established post-transcriptional control as a key node setting FMO2 levels in cardiac disease.

    Evidence RIP, RNA pulldown, luciferase, mRNA stability assays, TAC and LAD-ligation MI mouse models

    PMID:40021568 PMID:40610856

    Open questions at the time

    • Precise 3'UTR binding sites not mapped to nucleotide resolution
    • Interplay between transcriptional (KLF4) and post-transcriptional control unexamined
11. 2025 Medium

    Roles in cancer-associated fibroblasts and endothelial cells extended FMO2 function to tumor immunity and angiogenesis through competitive protein binding and metabolite regulation.

    Evidence Co-IP competitive binding (GYS1/PJA1), metabolomics (N-acetylornithine), orthotopic HCC and retinal/ischemic models, scRNA-seq, spatial transcriptomics

    PMID:40316306 PMID:41053533

    Open questions at the time

    • Single-lab findings without independent replication
    • Whether enzymatic activity underlies metabolite changes not cleanly separated from scaffolding

• It remains unresolved how FMO2's classical oxygenase activity relates mechanistically to its multiple enzyme-independent scaffolding functions, and whether the catalytically inactive human truncation retains any of these moonlighting roles.
• No structural model linking catalytic and scaffolding states
• Human truncated allele not tested in the non-catalytic interaction assays
• Tissue-specific partner repertoire incompletely mapped